SEARCH RESULTS FOR:

United States
Pharma & Life Sciences

From Volume to Value: A Shift in Innovation Focus in the U.S.

United States Biopharmaceuticals 2018
Precision medicine and the understanding that every patient is different are driving drug discovery.
United States
Pharma & Life Sciences

Eugene Williams

EXECUTIVE CHAIRMAN, PROMIS
United States Biopharmaceuticals 2018
ProMIS Neurosciences is a development-stage biotech company focused on neurodegenerative diseases, particularly Alzheimer’s disease and ALS.
Petrochemicals & Chemicals
India

M P Aggrawal

CHAIRMAN, SAJJAN INDIA LIMITED
Sajjan is an Indian contract manufacturer with expertise in large-scale production of active ingredients, electronic chemicals, specialty chemicals and intermediates with applications in agrochemicals, pharmaceuticals and dyes.
Petrochemicals & Chemicals
Singapore

Singapore Chemicals 2018

Mining
Zambia
DRC
MACIG

MACIG 2019 Pre-Release

Mining
Australia
Zambia
DRC
Tanzania
MACIG

Bill Witham

CEO, AAMEG
AAMEG endeavors to provide Australian companies operating in Africa with a platform to network and discuss critical issues facing the industry today.
Mining
Turkey

Adding Value to Turkey: Mineral Processing and Turkey’s Maturing Mining Industry

The recognition that Turkey’s miners must add more value to what they produce reflects the maturity of Turkey’s mining industry.
Mining
Peru

A World of Innovation

Peru Mining 2018 Pre-Release 2
Technology providers keep incorporating new concepts to improve productivity and safety in Peru.
Mining
Zambia
MACIG

John Gladston

GOVERNMENT AFFAIRS MANAGER, FIRST QUANTUM MINERALS (FQM)
FQM explains to GBR the operational challenges in Zambia where the company plays a crucial economic role.
Mining
Ecuador

Henry Troya

VICE-MINISTER OF MINING, GOVERNMENT OF ECUADOR
The Vice-minister for Mining of Ecuador explains why the country is now finally ready to open its doors to mining investments.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL